Zinc enhances chemosensitivity to paclitaxel in PC‑3 prostate cancer cells

Zhang, Ping; Li, Yang; Tang, Xinyu; Guo, Rui; Li, Jiuling; Chen, Ying Ying; Guo,Hua; Su,Jing; Sun,Liankun; Liu,Yanan

doi:10.3892/or.2018.6622

Zinc enhances chemosensitivity to paclitaxel in PC‑3 prostate cancer cells

Authors:
- Ping Zhang
- Yang Li
- Xinyu Tang
- Rui Guo
- Jiuling Li
- Ying Ying Chen
- Hua Guo
- Jing Su
- Liankun Sun
- Yanan Liu
View Affiliations

Affiliations: Department of Pathophysiology, Prostate Diseases Prevention and Treatment Research Center, School of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Pathophysiology, Prostate Diseases Prevention and Treatment Research Center, School of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: August 2, 2018 https://doi.org/10.3892/or.2018.6622
Pages: 2269-2277

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paclitaxel‑based chemotherapy is a promising approach for prostate cancer treatment. However, single‑drug chemotherapy is associated with an increased risk of drug resistance. Therefore, novel combination chemotherapy regimens are a popular topic of research. Zinc participates in the regulation of apoptosis, for example in the form of Zn2+ and via zinc‑dependent enzymes. Zinc can either induce or suppress apoptosis, and its effect depends primarily on its concentration. Previous research has demonstrated that physiological concentrations of zinc can directly induce apoptosis of PC‑3 prostate cancer cells via the mitochondrial pathway. In prostate cancer tissues, zinc concentrations have been demonstrated to be reduced compared with non-cancerous tissues. Furthermore, the concentration of zinc has been demonstrated to decrease further with cancer progression. In the present study, it was investigated whether exposure of PC‑3 cells to zinc improved their sensitivity to the chemotherapeutic agent, paclitaxel. MTT assays, cell clone formation assays, Hoechst staining and flow cytometry revealed that zinc enhanced PC‑3‑cell chemosensitivity to paclitaxel. Western blotting and reverse transcription‑polymerase chain reaction were used to determine that the mitochondria‑mediated apoptosis signaling pathway is involved with zinc/paclitaxel‑induced cell death. The present study provides a foundation for the development of novel tumor combination therapy.

View Figures

View References

1	Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer. Lancet. 387:70–82. 2016. View Article : Google Scholar : PubMed/NCBI
2	Lavery HJ and Cooperberg MR: Clinically localized prostate cancer in 2017: A review of comparative effectiveness. Urol Oncol. 35:40–41. 2017. View Article : Google Scholar : PubMed/NCBI
3	Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A and Blandino G: Mutant p53: An oncogenic transcription factor. Oncogene. 26:2212–2219. 2007. View Article : Google Scholar : PubMed/NCBI
4	Gan L, Wang J, Xu H and Yang X: Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate. 71:1158–1166. 2011. View Article : Google Scholar : PubMed/NCBI
5	Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC and Fojo T: A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA. 97:2904–2909. 2000. View Article : Google Scholar : PubMed/NCBI
6	Li Y, Mizokami A, Izumi K, Narimoto K, Shima T, Zhang J, Dai J, Keller ET and Namiki M: CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. Prostate. 70:48–60. 2010. View Article : Google Scholar : PubMed/NCBI
7	Li Y, Zeng Y, Mooney SM, Yin B, Mizokami A, Namiki M and Getzenberg RH: Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. J Cell Biochem. 112:2125–2137. 2011. View Article : Google Scholar : PubMed/NCBI
8	Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET and Namiki M: The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate. 67:955–967. 2007. View Article : Google Scholar : PubMed/NCBI
9	Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y and Huang H: Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 69:8386–8394. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ting HJ, Hsu J, Bao BY and Lee YF: Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. Cancer Lett. 247:122–129. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ding WQ, Yu HJ and Lind SE: Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Lett. 271:251–259. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kim S, Seo JW, Oh SB, Kim SH, Kim I, Suh N and Lee JY: Disparate roles of zinc in chemical hypoxia-induced neuronal death. Front Cell Neurosci. 9:12015. View Article : Google Scholar : PubMed/NCBI
13	Zhao Y, Tan Y, Dai J, Wang B, Li B, Guo L, Cui J, Wang G, Li W and Cai L: Zinc deficiency exacerbates diabetic down-regulation of Akt expression and function in the testis: Essential roles of PTEN, PTP1B and TRB3. J Nutr Biochem. 23:1018–1026. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kayatekin C, Zitzewitz JA and Matthews CR: Zinc binding modulates the entire folding free energy surface of human Cu, Zn superoxide dismutase. J Mol Biol. 384:540–555. 2008. View Article : Google Scholar : PubMed/NCBI
15	Fanzo JC, Reaves SK, Cui L, Zhu L, Wu JY, Wang YR and Lei KY: Zinc status affects p53, gadd45, and c-fos expression and caspase-3 activity in human bronchial epithelial cells. Am J Physiol Cell Physiol. 281:C751–C757. 2001. View Article : Google Scholar : PubMed/NCBI
16	Kelleher SL, McCormick NH, Velasquez V and Lopez V: Zinc in specialized secretory tissues: Roles in the pancreas, prostate, and mammary gland. Adv Nutr. 2:101–111. 2011. View Article : Google Scholar : PubMed/NCBI
17	Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, et al: Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer. 131:E562–E568. 2012. View Article : Google Scholar : PubMed/NCBI
18	Kloubert V and Rink L: Zinc as a micronutrient and its preventive role of oxidative damage in cells. Food Funct. 6:3195–3204. 2015. View Article : Google Scholar : PubMed/NCBI
19	Carraway RE and Dobner PR: Zinc pyrithione induces ERK- and PKC-dependent necrosis distinct from TPEN-induced apoptosis in prostate cancer cells. Biochim Biophys Acta. 1823:544–557. 2012. View Article : Google Scholar : PubMed/NCBI
20	Gallus S, Foschi R, Negri E, Talamini R, Franceschi S, Montella M, Ramazzotti V, Tavani A, Dal Maso L and La Vecchia C: Dietary zinc and prostate cancer risk: A case-control study from Italy. Eur Urol. 52:1052–1056. 2007. View Article : Google Scholar : PubMed/NCBI
21	Seth R, Corniola RS, Gower-Winter SD, Morgan TJ Jr, Bishop B and Levenson CW: Zinc deficiency induces apoptosis via mitochondrial p53- and caspase-dependent pathways in human neuronal precursor cells. J Trace Elem Med Biol. 30:59–65. 2015. View Article : Google Scholar : PubMed/NCBI
22	Gu J, Wang B, Liu Y, Zhong L, Tang Y, Guo H, Jiang T, Wang L, Li Y and Cai L: Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. Eur J Cancer. 50:1184–1194. 2014. View Article : Google Scholar : PubMed/NCBI
23	Shao Y, Liu Y, Shao C, Hu J, Li X, Li F, Zhang L, Zhao D, Sun L, Zhao X, et al: Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein. Cancer Gene Ther. 17:844–854. 2010. View Article : Google Scholar : PubMed/NCBI
24	Bataineh ZM, Hani Bani IH and Al-Alami JR: Zinc in normal and pathological human prostate gland. Saudi Med J. 23:218–220. 2002.PubMed/NCBI
25	Wang C, Huang SB, Yang MC, Lin YT, Chu IH, Shen YN, Chiu YH, Hung SH, Kang L, Hong YR, et al: Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells. PLoS One. 10:e01209132015. View Article : Google Scholar : PubMed/NCBI
26	Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW and Gao AC: Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 73:418–427. 2013. View Article : Google Scholar : PubMed/NCBI
27	Krone CA and Harms LC: Re: Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst. 95:1556–1557. 2003. View Article : Google Scholar : PubMed/NCBI
28	Costello LC and Franklin RB: The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: Connecting the dots. Mol Cancer. 5:172006. View Article : Google Scholar : PubMed/NCBI
29	Stepien M, Hughes DJ, Hybsier S, Bamia C, Tjonneland A, Overvad K, Affret A, His M, Boutron-Ruault MC, Katzke V, et al: Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans. Br J Cancer. 116:688–696. 2017. View Article : Google Scholar : PubMed/NCBI
30	Costello LC, Franklin RB and Feng P: Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion. 5:143–153. 2005. View Article : Google Scholar : PubMed/NCBI
31	Yang Y, Zong M, Xu W, Zhang Y, Wang B, Yang M and Tao L: Natural pyrethrins induces apoptosis in human hepatocyte cells via Bax- and Bcl-2-mediated mitochondrial pathway. Chem Biol Interact. 262:38–45. 2017. View Article : Google Scholar : PubMed/NCBI
32	Shan M and Fan TJ: Cytotoxicity of carteolol to human corneal epithelial cells by inducing apoptosis via triggering the Bcl-2 family protein-mediated mitochondrial pro-apoptotic pathway. Toxicol In Vitro. 35:36–42. 2016. View Article : Google Scholar : PubMed/NCBI
33	Gibson CJ and Davids MS: BCL-2 Antagonism to target the intrinsic mitochondrial pathway of apoptosis. Clin Cancer Res. 21:5021–5029. 2015. View Article : Google Scholar : PubMed/NCBI